Skip to main content
NCBI home page
Gut logoLink to Gut
. 1992 Oct;33(10):1348–1352. doi: 10.1136/gut.33.10.1348

Tests of renal function in patients with quiescent colitis: effects of drug treatment.

S A Riley 1, D R Lloyd 1, V Mani 1
PMCID: PMC1379602  PMID: 1446858

Abstract

Mesalazine has structural similarities to aspirin and phenacetin and is nephrotoxic when given intravenously in high doses to rats. A number of cases of nephrotoxicity has been reported recently in patients taking oral mesalazine. Sensitive indicators of renal function in a group of patients maintained on long term, delayed release mesalazine and a comparable group on sulphasalazine have been studied. Sixty two patients (32 men, aged 28-82 years) with quiescent colitis were studied. Thirty four had been maintained on delayed release mesalazine 1.6 (0.8-2.4) g/day for 2.9 (0.5-6.9) years and 28 on sulphasalazine 2 (2-3) g/day. Groups were comparable for age, sex, disease duration, and disease extent. Renal function was assessed by: urine microscopy; creatinine clearance; the urinary excretion of two markers of glomerular toxicity, albumin and transferrin; and the urinary excretion for two markers of tubular toxicity, N-acetyl-beta-D-glucosaminidase (NAG) and alpha 1-microglobulin. There were no significant differences in renal function between the two treatment groups. Furthermore, no correlations were found between measures of renal function and either cumulative mesalazine dose or mesalazine treatment duration. In this study, long term maintenance treatment with delayed release mesalazine was no more nephrotoxic than continued treatment with sulphasalazine.

Full text

PDF
1348

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arnold L., Collins C., Starmer G. A. The short-term effects of analgesics on the kidney with special reference to acetylsalicylic acid. Pathology. 1973 Apr;5(2):123–134. doi: 10.3109/00313027309060827. [DOI] [PubMed] [Google Scholar]
  2. BRANDER L., KUHLBACK B., NIEMISTO M., RISKA N. The effect of massive doses of PAS on renal function and electrolyte balance. Scand J Clin Lab Invest. 1963;15 (Suppl 69):38–43. [PubMed] [Google Scholar]
  3. Barbour V. M., Williams P. F. Nephrotic syndrome associated with sulphasalazine. BMJ. 1990 Oct 6;301(6755):818–818. doi: 10.1136/bmj.301.6755.818-b. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Bilyard K. G., Joseph E. C., Metcalf R. Mesalazine: an overview of key preclinical studies. Scand J Gastroenterol Suppl. 1990;172:52–55. doi: 10.3109/00365529009091911. [DOI] [PubMed] [Google Scholar]
  5. Bondesen S., Nielsen O. H., Schou J. B., Jensen P. H., Lassen L. B., Binder V., Krasilnikoff P. A., Danø P., Hansen S. H., Rasmussen S. N. Steady-state kinetics of 5-aminosalicylic acid and sulfapyridine during sulfasalazine prophylaxis in ulcerative colitis. Scand J Gastroenterol. 1986 Aug;21(6):693–700. doi: 10.3109/00365528609011102. [DOI] [PubMed] [Google Scholar]
  6. Calder I. C., Funder C. C., Green C. R., Ham K. N., Tange J. D. Comparative nephrotoxicity of aspirin and phenacetin derivatives. Br Med J. 1971 Nov 27;4(5786):518–521. doi: 10.1136/bmj.4.5786.518. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Calder I. C., Funder C. C., Green C. R., Ham K. N., Tange J. D. Nephrotoxic lesions from 5-aminosalicylic Acid. Br Med J. 1972 Jan 15;1(5793):152–154. doi: 10.1136/bmj.1.5793.152. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Chester A. C., Diamond L. H., Schreiner G. E. Hypersensitivity to salicylazosulfapyridine: renal and hepatic toxic reactions. Arch Intern Med. 1978 Jul;138(7):1138–1139. doi: 10.1001/archinte.138.7.1138. [DOI] [PubMed] [Google Scholar]
  9. Christensen L. A., Fallingborg J., Abildgaard K., Jacobsen B. A., Sanchez G., Hansen S. H., Bondesen S., Hvidberg E. F., Rasmussen S. N. Topical and systemic availability of 5-aminosalicylate: comparisons of three controlled release preparations in man. Aliment Pharmacol Ther. 1990 Oct;4(5):523–533. doi: 10.1111/j.1365-2036.1990.tb00499.x. [DOI] [PubMed] [Google Scholar]
  10. Dew M. J., Harries A. D., Evans N., Evans B. K., Rhodes J. Maintenance of remission in ulcerative colitis with 5-amino salicylic acid in high doses by mouth. Br Med J (Clin Res Ed) 1983 Jul 2;287(6384):23–24. doi: 10.1136/bmj.287.6384.23. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Diener U., Tuczek H. V., Fischer C., Maier K., Klotz U. Renal function was not impaired by treatment with 5-aminosalicylic acid in rats and man. Naunyn Schmiedebergs Arch Pharmacol. 1984 Jun;326(3):278–282. doi: 10.1007/BF00505331. [DOI] [PubMed] [Google Scholar]
  12. Dissanayake A. S., Truelove S. C. A controlled therapeutic trial of long-term maintenance treatment of ulcerative colitis with sulphazalazine (Salazopyrin). Gut. 1973 Dec;14(12):923–926. doi: 10.1136/gut.14.12.923. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Dubach U. C., Rosner B., Stürmer T. An epidemiologic study of abuse of analgesic drugs. Effects of phenacetin and salicylate on mortality and cardiovascular morbidity (1968 to 1987) N Engl J Med. 1991 Jan 17;324(3):155–160. doi: 10.1056/NEJM199101173240304. [DOI] [PubMed] [Google Scholar]
  14. Gabriel R. Time to scrap creatinine clearance? Br Med J (Clin Res Ed) 1986 Nov 1;293(6555):1119–1120. doi: 10.1136/bmj.293.6555.1119. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Ginsberg J. M., Chang B. S., Matarese R. A., Garella S. Use of single voided urine samples to estimate quantitative proteinuria. N Engl J Med. 1983 Dec 22;309(25):1543–1546. doi: 10.1056/NEJM198312223092503. [DOI] [PubMed] [Google Scholar]
  16. Grossman M. S., Nugent F. W. Urolithiasis as a complication of chronic diarrheal disease. Am J Dig Dis. 1967 May;12(5):491–498. doi: 10.1007/BF02233181. [DOI] [PubMed] [Google Scholar]
  17. Hayllar J., Bjarnason I. Sulphasalazine in ulcerative colitis: in memoriam? Gut. 1991 May;32(5):462–463. doi: 10.1136/gut.32.5.462. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Husdan H., Rapoport A. Estimation of creatinine by the Jaffe reaction. A comparison of three methods. Clin Chem. 1968 Mar;14(3):222–238. [PubMed] [Google Scholar]
  19. Koutras A., Daum F., Das K. M., Markowitz J., Duffy L., Aiges H., Atkinson M., Fisher S. E. Sulfasalazine and renal tubular function: lack of an effect. J Pediatr Gastroenterol Nutr. 1985 Feb;4(1):103–106. doi: 10.1097/00005176-198502000-00019. [DOI] [PubMed] [Google Scholar]
  20. Lloyd D. R., Hindle E. J., Marples J., Gatt J. A. Urinary albumin measurement by immunoturbidimetry. Ann Clin Biochem. 1987 Mar;24(Pt 2):209–210. doi: 10.1177/000456328702400218. [DOI] [PubMed] [Google Scholar]
  21. Lockwood T. D., Bosmann H. B. The use of urinary N-acetyl-beta-glucosaminidase in human renal toxicology. II. Elevation in human excretion after aspirin and sodium salicylate. Toxicol Appl Pharmacol. 1979 Jun 30;49(2):337–345. doi: 10.1016/0041-008x(79)90258-8. [DOI] [PubMed] [Google Scholar]
  22. Mogensen C. E. Microalbuminuria as a predictor of clinical diabetic nephropathy. Kidney Int. 1987 Feb;31(2):673–689. doi: 10.1038/ki.1987.50. [DOI] [PubMed] [Google Scholar]
  23. Novis B. H., Korzets Z., Chen P., Bernheim J. Nephrotic syndrome after treatment with 5-aminosalicylic acid. Br Med J (Clin Res Ed) 1988 May 21;296(6634):1442–1442. doi: 10.1136/bmj.296.6634.1442. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Payne R. B. Creatinine clearance: a redundant clinical investigation. Ann Clin Biochem. 1986 May;23(Pt 3):243–250. doi: 10.1177/000456328602300304. [DOI] [PubMed] [Google Scholar]
  25. Price R. G. Urinary enzymes, nephrotoxicity and renal disease. Toxicology. 1982;23(2-3):99–134. doi: 10.1016/0300-483x(82)90092-0. [DOI] [PubMed] [Google Scholar]
  26. Proctor R. A., Kunin C. M. Salicylate-induced enzymuria: comparison with other anti-inflammatory agents. Am J Med. 1978 Dec;65(6):987–993. doi: 10.1016/0002-9343(78)90751-9. [DOI] [PubMed] [Google Scholar]
  27. Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ. 1989 Jan 14;298(6666):82–86. doi: 10.1136/bmj.298.6666.82. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Rand J. A., Brandt L. J., Becker N. H., Lynch J. Ulcerative colitis complicated by amyloidosis. Am J Gastroenterol. 1980 Aug;74(2):185–187. [PubMed] [Google Scholar]
  29. Riley S. A., Mani V., Goodman M. J., Herd M. E., Dutt S., Turnberg L. A. Comparison of delayed release 5 aminosalicylic acid (mesalazine) and sulphasalazine in the treatment of mild to moderate ulcerative colitis relapse. Gut. 1988 May;29(5):669–674. doi: 10.1136/gut.29.5.669. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Riley S. A., Mani V., Goodman M. J., Herd M. E., Dutt S., Turnberg L. A. Comparison of delayed-release 5-aminosalicylic acid (mesalazine) and sulfasalazine as maintenance treatment for patients with ulcerative colitis. Gastroenterology. 1988 Jun;94(6):1383–1389. doi: 10.1016/0016-5085(88)90677-4. [DOI] [PubMed] [Google Scholar]
  31. Riley S. A., Turnberg L. A. Sulphasalazine and the aminosalicylates in the treatment of inflammatory bowel disease. Q J Med. 1990 Jun;75(278):551–562. [PubMed] [Google Scholar]
  32. Rutgeerts P. Comparative efficacy of coated, oral 5-aminosalicylic acid (Claversal) and sulphasalazine for maintaining remission of ulcerative colitis. International Study Group. Aliment Pharmacol Ther. 1989 Apr;3(2):183–191. [PubMed] [Google Scholar]
  33. Sandler D. P., Smith J. C., Weinberg C. R., Buckalew V. M., Jr, Dennis V. W., Blythe W. B., Burgess W. P. Analgesic use and chronic renal disease. N Engl J Med. 1989 May 11;320(19):1238–1243. doi: 10.1056/NEJM198905113201903. [DOI] [PubMed] [Google Scholar]
  34. Schroeder K. W., Tremaine W. J., Ilstrup D. M. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987 Dec 24;317(26):1625–1629. doi: 10.1056/NEJM198712243172603. [DOI] [PubMed] [Google Scholar]
  35. Schwab S. J., Christensen R. L., Dougherty K., Klahr S. Quantitation of proteinuria by the use of protein-to-creatinine ratios in single urine samples. Arch Intern Med. 1987 May;147(5):943–944. [PubMed] [Google Scholar]
  36. Staerk Laursen L., Stokholm M., Bukhave K., Rask-Madsen J., Lauritsen K. Disposition of 5-aminosalicylic acid by olsalazine and three mesalazine preparations in patients with ulcerative colitis: comparison of intraluminal colonic concentrations, serum values, and urinary excretion. Gut. 1990 Nov;31(11):1271–1276. doi: 10.1136/gut.31.11.1271. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Walton C., Bodansky H. J., Wales J. K., Forbes M. A., Cooper E. H. Tubular dysfunction and microalbuminuria in insulin dependent diabetes. Arch Dis Child. 1988 Mar;63(3):244–249. doi: 10.1136/adc.63.3.244. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Witherspoon L. R., el Shami A. S., Shuler S. E., Neely H., Sonnemaker R., Gilbert S. S., Alyea K. Chemically blocked analog assays for free thyronines. I. The effect of chemical blockers on T4 analog and T4 binding by albumin and by thyroxin-binding globulin. Clin Chem. 1988 Jan;34(1):9–16. [PubMed] [Google Scholar]
  39. von Mühlendahl K. E. Nephritis durch 5-Aminosalicylsäure. Dtsch Med Wochenschr. 1989 Feb 10;114(6):236–236. [PubMed] [Google Scholar]

Articles from Gut are provided here courtesy of BMJ Publishing Group

RESOURCES